[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO5011105A1 - Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion - Google Patents

Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion

Info

Publication number
CO5011105A1
CO5011105A1 CO98075202A CO98075202A CO5011105A1 CO 5011105 A1 CO5011105 A1 CO 5011105A1 CO 98075202 A CO98075202 A CO 98075202A CO 98075202 A CO98075202 A CO 98075202A CO 5011105 A1 CO5011105 A1 CO 5011105A1
Authority
CO
Colombia
Prior art keywords
carbon atoms
atoms
carbon
alkoxy
alkyl
Prior art date
Application number
CO98075202A
Other languages
English (en)
Inventor
Peter Buehlmayer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5011105A1 publication Critical patent/CO5011105A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con un compuesto de lafórmula I: donde X es S ó NH, e Y y Z son cada uno CH; o X es NH, es una de las variables Y y Z es N, y la otra es CH; R1 y R2 , independientemente uno del otro, representan hidrógeno, alquilo de 1 a 7 átomos de carbono, o alquilo de 1 a 7 átomos de carbono sustituido por hidroxi, halógeno, alcoxi de 1 a 7 átomos de carbono, carboxi, alcoxi, de 1 a 7 átomos de carbono-carbonilo, carbamoílo, alquilo de 1 a 7 átomos de carbono-carbamoílo, dialquilo de 1 a 7 átomos de carbono-carbamoílo, cicloalquilo de 3 a 8 átomos de carbono, por cicloalquilo de 3 a 8 átomos de carbono que está sustituido por alcoxi de 1 a 7 átomos de carbono-carbonilo, o representan alcanoílo de 2 a 7 átomos de carbono; mientras que cuando menos una de las variables R1 y R2 es diferente de hidrógeno; o el grupo NR1 R2 alquileno de 2 a 6 átomos de carbono-amino lineal que está insustituido a sustituido por alquilo de 1 a 7 átomos de carbono, hidroxialquilo de 1 a 7 átomos de carbono, alcoxi de 1 a 7 átomos de carbono, alcoxi de 1 a 7 átomos de carbono, alcoxi de 1 a 7 átomos de carbono-alcoxi de 1 a 7 átomos de carbono-alquilo de 1 a 7 átomos de carbono, tioalquilo de 1 a 7 átomos de carbono-alquilo de 1 a 7 átomos de carbono, alcano 1 a 7 átomos de carbono, alcano de 1 a 7 átomos de carbono-sulfonialquilo de 1 a 7 átomos de carbono, aminoalquilo de 1 a 7 átomos de carbono, alquilo de 1 a 7 átomos de carbono-aminoalquilo de 1 a 7 átomos de carbono, dialquilo de 1 a 7 átomos de carbono-aminoalquilo de 1 a 7 átomos de carbono, hidroxi, ciano, amino, alquilo de 1 a 7 átomos de carbono-amino, dialquilo de 1 a 7 átomos de carbono-amino, alcanoílo de 1 a 7 átomos de carbono, hidroxiliminoalquilo de 2 a 7 átomos de carbono, carboxi, alcoxi de 1 a 7 átomos de carbono-carbamoílo, dialquilo de 1 a 7 átomos de carbono-carbamoílo, o por oxo, ...
CO98075202A 1997-12-22 1998-12-17 Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion CO5011105A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19757248 1997-12-22

Publications (1)

Publication Number Publication Date
CO5011105A1 true CO5011105A1 (es) 2001-02-28

Family

ID=7853006

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98075202A CO5011105A1 (es) 1997-12-22 1998-12-17 Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion

Country Status (6)

Country Link
AR (1) AR014406A1 (es)
AU (1) AU2415299A (es)
CO (1) CO5011105A1 (es)
PE (1) PE20000127A1 (es)
WO (1) WO1999032466A1 (es)
ZA (1) ZA9811705B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE314371T1 (de) 1998-11-10 2006-01-15 Merck & Co Inc Spiro-indole als y5-rezeptor antagonisten
FR2792314B1 (fr) * 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
CA2371274A1 (en) * 1999-04-22 2000-11-02 Synaptic Pharmaceutical Corporation Selective npy (y5) antagonists
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6222040B1 (en) 1999-06-30 2001-04-24 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
US6214853B1 (en) 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
DK2014285T3 (da) * 1999-11-26 2010-06-28 Shionogi & Co NPYY5-antagonister
ATE414079T1 (de) 2000-03-01 2008-11-15 Janssen Pharmaceutica Nv 2,4-disubstituierte thiazolyl derivate
FR2815346B1 (fr) * 2000-10-13 2004-02-20 Servier Lab Nouveaux composes aminotriazolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002078697A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
CA2403307A1 (en) 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
CN1794989A (zh) * 2003-04-14 2006-06-28 药物研发有限责任公司 用于治疗糖尿病的n－(((((1,3－噻唑－2－基)氨基)羰基)苯基)磺酰基)苯丙氨酸衍生物及相关化合物
EA200501710A1 (ru) 2003-04-30 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые карбоновые кислоты
US7888380B2 (en) * 2004-10-08 2011-02-15 Janssen Pharmaceutica, N.V. 1,2,4-Triazolylaminoaryl (heteroaryl) sulfonamide derivatives
GB0526257D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP3052190A4 (en) * 2013-10-01 2017-07-19 New York University Amino, amido, and heterocyclic compounds as modulators of rage activity and uses thereof
EP4077290A1 (en) 2019-12-20 2022-10-26 Ikena Oncology, Inc. 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776765A (en) * 1972-02-28 1973-12-04 Cities Service Co Process for protecting a substrate with an n{11 substituted aminoarylsulfonamide intumescent agent
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
CA2195847A1 (en) * 1994-07-27 1996-02-08 John J. Talley Substituted thiazoles for the treatment of inflammation

Also Published As

Publication number Publication date
PE20000127A1 (es) 2000-03-14
ZA9811705B (en) 1999-09-07
AU2415299A (en) 1999-07-12
AR014406A1 (es) 2001-02-28
WO1999032466A1 (en) 1999-07-01

Similar Documents

Publication Publication Date Title
CO5011105A1 (es) Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion
BR0010555A (pt) Inibidores de neuraminidases
ES2189330T3 (es) Derivados heterociclicos n6 de la adenosina sustituidos.
BR0111230A (pt) Composto, e, uso e processo para a preparação do mesmo
CO5011039A1 (es) Inhibidores de metaloproteasa hidroxamato de pirrolidina sustituidos
BR0213455A (pt) Composto, seu uso, composição farmacêutica, método para o tratamento ou prevenção de uma doença para a qual um receptor adenosina está relacionado, e método para promover a defecação
BR0109109A (pt) Composto, uso do mesmo, processo para prepará-lo, composição farmacêutica, e, método de tratar um estado doentio mediado por ccr5 em mamìferos
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen
ES2195034T3 (es) Inhibidor de metaloproteinasas, composicion farmaceutica que contiene este inhibidor y su utilizacion farmaceutica, y procedimientos que sirven para su preparacion.
BR0315913A (pt) Composições retardantes de chama
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
UY25142A1 (es) Antagonistas del receptor ccr-3
BR9913654A (pt) Inibidores de p-38alfa quinase
ES2148715T3 (es) Mezcla sinergetica de estabilizadores.
PT1037886E (pt) Inibidores de angiogenese de triazina
UY28877A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida y composiciones
ES2059335T3 (es) Derivados de pirido(3,2,1-ij)-1,3,4-benzoxadiazina, procedimiento para su obtencion, preparados farmaceuticos correspondientes y productos intermedios utilizables en el procedimiento.
AR013875A1 (es) Compuesto 2-imidazolinilaminoindol, composicion farmaceutica que comprende dicho compuesto y uso del mismo para la fabricacion de un medicamento.
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
BR0116365A (pt) Uso de um composto, composto, derivado de 3-indolina, composição farmacêutica, e, método de tratamento de sintomas positivos ou negativos
AR002690A1 (es) Derivado de bencimidazol o sales del mismo, composicion farmaceutica, agente inmunosupresor y agente antiinflamatorio que lo contienen yprocedimientos para preparar dicho derivado.
AR007969A1 (es) Compuestos derivados de pirroles sustituidos, su utilizacion y composiciones farmaceuticas que contienen tales compuestos
CR10974A (es) Inhibidores de carboxipeptidasa b plasmatica (divisional)
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
ATE344230T1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen